126 related articles for article (PubMed ID: 11474273)
21. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
[TBL] [Abstract][Full Text] [Related]
22. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
23. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Pacetti U; Carlini P; Ruggeri EM; Cognetti F
Cancer Chemother Pharmacol; 2001 Sep; 48(3):255-8. PubMed ID: 11592349
[TBL] [Abstract][Full Text] [Related]
25. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
26. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
27. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Kanat O; Evrensel T; Baran I; Coskun H; Zarifoglu M; Turan OF; Kurt E; Demiray M; Gonullu G; Manavoglu O
Med Oncol; 2003; 20(3):237-45. PubMed ID: 14514973
[TBL] [Abstract][Full Text] [Related]
29. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
30. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
31. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
[TBL] [Abstract][Full Text] [Related]
34. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
[TBL] [Abstract][Full Text] [Related]
35. Amifostine in clinical oncology: current use and future applications.
Koukourakis MI
Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Otterson GA; Lavelle J; Villalona-Calero MA; Shah M; Wei X; Chan KK; Fischer B; Grever M
Invest New Drugs; 2005 Dec; 23(6):555-62. PubMed ID: 16034523
[TBL] [Abstract][Full Text] [Related]
37. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
38. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Garzetti GG; Ciavattini A; Muzzioli M; Romanini C
Cancer; 1999 May; 85(10):2226-31. PubMed ID: 10326702
[TBL] [Abstract][Full Text] [Related]
40. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
